Diligence memo · auto-generated · as of July 2, 2026
ADvantage Therapeutics, Inc.
ADvantage Therapeutics, Inc. looks over-valued against its niche peers and is at-risk on financing cadence.
Businessfiled
ADvantage Therapeutics, Inc. operates in Pharma, based in Miami.
Sub-sector tags: pharma.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
ADvantage Therapeutics, Inc. has raised $19M in disclosed capital across 3 recorded rounds, aggregated from public filings. Its latest round is modeled as Series A (a $4.0M–$15M round).
Largest single filing: $14M on 2023-06-28.
Most recent recorded round closed around 2023-06-28.
Valuation (modeled)modeled
Provath models ADvantage Therapeutics, Inc. at approximately $111M (range $16M–$304M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Over-valued. Modeled value is 1.63× the median modeled value of Series A Pharma companies in 2022–2024 (24 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Historic cadence: a new round about every 8 months.
Last raise 3.0 yr ago; this sector typically re-raises about every 16 months.
Past due for a raise versus sector cadence — watch for distress or a bridge.
The last round was 1.3× smaller than the prior — a bridge or down round.
Comparablesmixed
Capital scale ranks ahead of 75% of Pharma peers (310 compared).
Modeled value ranks above 67% of those peers.
Closest niche peers: Carmine Therapeutics, Inc., Triomics, Inc., Spiral Therapeutics Inc, Convelo Therapeutics, Inc., Galaxy Therapeutics Inc..
Peoplefiled
6 named people on file across officers, directors and signatories.
Risks & flagsmixed
Overdue for a raise versus sector norm — distress or bridge risk.
Modeled above niche peers — valuation risk on entry.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.